PAR-24-280 clinical observational R01 eligibility Guide
Updated 4 official sources
Quick Answer: PAR-24-280 is a NIAMS R01 for clinical observational studies in musculoskeletal, rheumatic, and skin diseases.
Full answer and how we checked it
It is clinical trial not allowed, can include data from standard-of-care treatment, and lists no companion opportunity. The budget cap is $475,000 in direct costs over 4 years, and the maximum project period is 4 years. November 2, 2026 is the last due date listed in PAR-24-280 (opens in a new tab), and the notice expires November 3, 2026.
Who this is for: NIAMS investigators, clinical observational study teams, registry researchers, rheumatology, orthopedics, dermatology, rehabilitation, and sponsored-research offices deciding whether a non-trial observational R01 fits.
Data note: This guide uses NIH PAR-24-280, the NIH clinical-trial definition, Grants.gov listing 357604, and Grantsights award-data signals checked on June 2, 2026.
Source review by Grantsights, June 3, 2026: We rechecked NIH PAR-24-280, NIH clinical-trial definitions, NIAMS clinical research context, Grants.gov listing 357604. Where official sources stop: PAR-24-280 is still an R01 clinical-trial-not-allowed route for clinical observational studies in musculoskeletal, rheumatic, and skin diseases, with standard-care exposure allowed only when the research protocol does not assign treatment.
In this guide
- June 2026 Source Check
- 6 PAR-24-280 Eligibility Stop Checks
- 5 Funding, Timing, and Mechanism Rules
- 5 R01 Versus R21 Route Choices
- What NIH Doesn't Tell You
- 6 Real-World PAR-24-280 Scenarios
- 7 Draft Checks to Run First
- 7 Evidence Assets That Make This R01 Stronger
- 21-Day Clinical Observational R01 Routing Plan
- 6 Reviewer-Risk Signals to Fix
- 6 Budget And Scope Questions Before Submission
- 5 Applicant Types and Best Next Move
- 7 Route Checks Added May 26, 2026
- Sources
PAR-24-280 isn't a back door for clinical trials. According to NIH PAR-24-280 (opens in a new tab), the NOFO supports clinical observational studies in musculoskeletal, rheumatic, and skin diseases and is clinical trial not allowed.
A clinical study can have strong science and still carry the wrong trial classification. That can sink an application before the study design gets a fair read.
Use this guide with the live NIAMS Clinical Observational R01 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, best NIH grants for researchers, what is a NOFO, and the Grantsights grant database.
June 2026 Source Check
PAR-24-280 remains active, but November 2, 2026 is its last listed due date and November 3, 2026 is its expiration date. Grantsights didn't find a reissued notice on Grants.gov as of October 10, 2026, so teams that can't make November 2 should watch the NIH Guide for a replacement before planning around this route. The March 31, 2025 source update tells applicants to reread the full opportunity and adjust applications before submission.
The official source screen is narrow: only clinical observational studies are supported, clinical trials are not allowed, non-U.S. organizations and non-U.S. components are not eligible, direct costs are limited to $475,000 over the 4-year period with no more than $250,000 in any single year, and standard-care exposure is only acceptable when the research protocol does not assign treatment.
Get grant deadline alerts by email
About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.
No spam. Unsubscribe anytime.
6 PAR-24-280 Eligibility Stop Checks
6 stop checks decide whether the R01 route fits before a 4-year observational study is planned. The project must be observational, NIAMS-relevant, non-trial, and mature enough for R01 scale.
| Stop check | Strong R01 signal | Red flag |
|---|---|---|
| Disease fit | Musculoskeletal, rheumatic, or skin disease is central | Disease focus is outside NIAMS scope |
| Study type | Observational clinical study | Research protocol assigns treatment |
| Standard care | Treatment exposure occurs as normal care | Investigator assigns intervention |
| Data plan | Cohort, registry, EHR, biospecimen, or outcomes data are credible | Data source is undefined |
| Mechanism scale | Multi-year R01 study is justified | Pilot-scale work would fit a smaller mechanism better |
| Outcome logic | Outcomes support future clinical studies or disease understanding | Measures are vague |
The first decision is clinical-trial status. If the investigator prospectively assigns an intervention to study a health outcome, this is likely the wrong route.
Don't wait until submission week to make that call. Trial-status uncertainty can change forms, budget, review expectations, and whether the application is accepted.
5 Funding, Timing, and Mechanism Rules
5 public rules should appear before drafting. NIH lists PAR-24-280 as an R01 clinical trial not allowed opportunity. Grantsights records the last listed due date as November 2, 2026. The NOFO lists no companion opportunity.
| Rule | Source-backed read |
|---|---|
| Funding number | PAR-24-280 |
| Mechanism | R01 research project grant |
| Clinical trial status | Not allowed |
| Companion opportunity | None listed |
| Last due date | November 2, 2026 |
| Maximum project period | 4 years |
| Budget cap | $475,000 direct costs over 4 years, max $250,000 in any year |
| Expiration date | November 3, 2026 |
According to NIH, observational additions to ongoing clinical studies that are not clinical trials are permitted when patients receive treatment as part of standard care, not as part of a research protocol. According to USAspending.gov (opens in a new tab) data, the connected NIAMS assistance listing (93.846) had about $535.2M in FY2024 obligations across 2,561 awards active that year.
5 R01 Versus R21 Route Choices
5 route choices matter within 21 days because PAR-24-280 has no companion R21. PAR-24-280 fits larger observational studies with strong design, data, and outcomes. Smaller exploratory or pilot-stage observational work needs a separate NIH notice, so check which current R21 or R03 notices NIAMS participates in before assuming a pilot route exists.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-24-280 R01 | Study is mature, multi-year, and observational | R01 scale fits |
| Separate R21 or R03 notice | Study is exploratory or pilot-stage | Check NIAMS participation first |
| Clinical-trial route | Investigator assigns intervention | PAR-24-280 bars trials |
| Parent R01 | NIAMS observational scope is not the right fit | Broader route may fit |
| Registry or foundation funds | Data infrastructure is not ready | Prep funding may come first |
For broader mechanism choice, use NIH R01 R21 R03 K awards comparison.
What NIH Doesn't Tell You
4 hidden readiness questions decide whether this belongs under PAR-24-280. NIH gives the source rules, but it does not decide whether the observational design is credible.
First, NIH does not make an observational study strong just because no intervention is assigned. Cohort definition, confounding, follow-up, data quality, and outcome validity still matter.
Second, NIH does not make standard-of-care exposure simple. The application should explain how treatment is chosen clinically and why the research team is not assigning it.
Third, NIH does not make R01 the default. If the registry, cohort, or data infrastructure is still forming, a smaller mechanism under a separate notice may be a better first step.
Fourth, NIH does not make every clinical study fit NIAMS. The disease, outcome, and future-study value should clearly support musculoskeletal, rheumatic, or skin disease research.
6 Real-World PAR-24-280 Scenarios
6 scenarios show where the route fits within its 4-year maximum project period. One registry-based study of rheumatic disease outcomes under standard care may fit. One investigator-assigned treatment comparison likely needs a clinical-trial route.
| Scenario | Better route | Why |
|---|---|---|
| Large observational cohort with standard-care exposure | PAR-24-280 R01 | Non-trial clinical study fits |
| Pilot registry feasibility study | Separate R21 or R03 notice | Smaller scope fits |
| Investigator assigns therapy | Clinical-trial route | PAR-24-280 bars trials |
| EHR study of skin disease symptoms | PAR-24-280 possible | Observational data can fit |
| Musculoskeletal outcomes after routine care | PAR-24-280 possible | Standard-care exposure fits |
| Disease area outside NIAMS | Parent R01 or other institute | Scope may miss |
For example, a team with a mature rheumatology registry, validated outcomes, and several years of follow-up data could fit. A team with only an idea for a new intervention assignment should not use this route.
7 Draft Checks to Run First
7 checks should happen before writing. They prevent clinical-trial classification and design mistakes.
- Confirm the study is not a clinical trial.
- Confirm the disease focus is musculoskeletal, rheumatic, or skin disease.
- Identify whether the project uses cohort, registry, EHR, biospecimen, or patient-reported outcome data.
- Explain how treatment exposure occurs through standard care if treatment is observed.
- Compare R01 scale with a smaller mechanism under a separate notice.
- Check that no year exceeds $250,000 in direct costs and the total stays within $475,000.
- Contact NIAMS program staff if clinical-trial status is uncertain.
According to NIH, the study may collect data on patients who receive treatment as part of standard care, not as part of a research study protocol.
7 Evidence Assets That Make This R01 Stronger
7 evidence assets make PAR-24-280 more than a non-trial label. The strongest applications show that the observational design can answer a NIAMS question without drifting into intervention testing.
First, define the disease group and why it belongs in the NIAMS clinical research program. According to NIH, this NOFO supports clinical observational studies in musculoskeletal, rheumatic, and skin diseases. The disease fit should be clear in the first page.
Second, prove that the study is observational. If clinicians choose treatment as part of normal care and the research team only observes outcomes, the route may fit. If the research protocol assigns treatment or changes care, avoid this NOFO.
Third, show the cohort source. Registry, EHR, clinic, imaging, biospecimen, wearable, telehealth, or patient-reported outcome data can all fit if collection and follow-up are credible.
Fourth, explain confounding before reviewers ask. Observational studies need a plan for treatment selection, disease severity, comorbidities, missingness, loss to follow-up, and sensitivity analyses.
Fifth, name the future clinical-study use. According to NIH, these studies can help plan future clinical research through outcome selection, recruitment strategy, biomarker validation, and disease timing. That link should be explicit.
Sixth, decide whether the R01 is earned. For example, a university team with a mature rheumatology registry, validated patient-reported outcomes, imaging, and existing follow-up data could make a strong R01 case. A team with a small new registry and no follow-up history should look for a smaller pilot mechanism first.
Seventh, write a trial-status memo. Have the PI, clinical lead, statistician, and sponsored-project office sign off on the classification before the team writes aims. That one document can prevent the wrong application package.
21-Day Clinical Observational R01 Routing Plan
21 days is enough to decide whether the team should draft. Days 1 through 3 should confirm source status, deadline, clinical-trial status, and NIAMS fit.
Days 4 through 7 should document the observational design. The team should state exposure, outcome, follow-up, confounders, data source, and why no research intervention is assigned.
Days 8 through 12 should compare R01 scale with smaller mechanisms. If data infrastructure or feasibility is weak, a pilot route under a separate notice may be better.
Days 13 through 16 should test the analysis plan. The application should address selection, missingness, confounding, measurement validity, and sensitivity analyses.
Days 17 through 21 should run NIH submission checks. The budget can't exceed $250,000 in direct costs in any year, so confirm every budget year fits the cap before routing.
6 Reviewer-Risk Signals to Fix
6 risk signals should be fixed before submission. First, the application should not blur observational research and intervention assignment.
Second, the disease focus should be clearly inside musculoskeletal, rheumatic, or skin disease.
Third, the cohort or data source should be mature enough for the aims.
Fourth, the analysis plan should handle confounding and missing data directly.
Fifth, patient-reported outcomes or clinical measures should be valid for the disease and study population.
Sixth, the project should show how the observational findings will inform future clinical studies, outcomes, or disease understanding.
6 Budget And Scope Questions Before Submission
6 budget questions should be answered before submission. According to NIH, PAR-24-280 limits direct costs to $475,000 over the 4 year period, with no more than $250,000 in any single year. That cap makes scope discipline more important than in many R01s.
The first question is whether the study can be done within the cap. A multi-site registry, imaging review, biospecimen work, patient-reported outcomes, and data coordination can exceed the budget quickly.
The second question is whether the outcome measures are already validated. If measurement work is still early, a smaller pilot mechanism may be a better fit.
The third question is whether recruitment and retention costs match the cohort plan. Observational does not mean cheap, especially when follow-up, images, records, or wearable data are part of the design.
The fourth question is whether data management is funded well enough. Missing visits, uneven EHR fields, imaging files, and patient-reported measures all need a clear data plan.
The fifth question is whether the statistical plan fits the budget. Confounding, sensitivity analyses, subgroup work, and missing-data plans require senior time.
The sixth question is whether the R01 creates more risk than value. Avoid building a 4-year project if a smaller pilot award could prove cohort feasibility, outcome reliability, or follow-up first.
5 Applicant Types and Best Next Move
5 applicant types commonly ask about PAR-24-280.
| Applicant type | Best next move | Why |
|---|---|---|
| Registry-based NIAMS team | Build R01 fit memo | Route may fit |
| Pilot observational team | Check separate R21 or R03 notices | No companion R21 exists |
| Intervention trial team | Use clinical-trial route | PAR-24-280 bars trials |
| EHR outcomes team | Test data quality | Observational route may fit |
| Sponsored-project office | Check trial status and budget | Technical issues can block |
The best answer is: use PAR-24-280 when the project is NIAMS-relevant, observational, non-trial, R01-ready, and supported by credible clinical data.
7 Route Checks Added May 26, 2026
Checked on May 26, 2026 against PAR-24-280 (opens in a new tab), the Grants.gov listing (opens in a new tab), Grants.gov (opens in a new tab), and USASpending.gov (opens in a new tab).
| Check | Public answer |
|---|---|
| Eligibility | Confirm the applicant, institution, and route rules for PAR-24-280 clinical observational R01 eligibility. |
| Source status | Verify the official listing, notices, due date, and expiration status. |
| Budget | Check award size, cost limits, match, or budget logic when the source provides it. |
| Evidence | Name the data, preliminary work, partner role, or implementation proof needed. |
| Bad fit | Stop if the project belongs in a nearby NIH or federal route. |
| Review criteria | Tie the first page to significance, approach, team, environment, and source-specific criteria. |
| Next action | Decide whether to draft, ask a program contact, or redirect to a nearby route. |
Final public checklist
- Confirm whether R01 is the right route or whether a nearby program fits better.
- Check budget, partner, match, or data-readiness constraints.
Sources
- NIH PAR-24-280 R01 NOFO: grants.nih.gov (opens in a new tab)
- Grants.gov listing 357604: grants.gov (opens in a new tab)
- Grantsights program record: NIAMS Clinical Observational R01
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open the R01 record
Check PAR-24-280, July 2026 timing, observational design, budget cap, and no-trial status.
Compare R01 and R21
Use when the cohort, registry, or measures may still be pilot-stage.
Review NIH submission
Check 5 p.m. local timing, forms, study classification, and NIH routing mechanics.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAR-24-280 fund?
NIH says the NOFO supports clinical observational studies in musculoskeletal, rheumatic, and skin diseases.
Are clinical trials allowed?
No. PAR-24-280 is clinical trial not allowed.
Can the study collect data from patients receiving standard care?
Yes. NIH says observational additions to ongoing clinical studies that are not clinical trials may include data from patients who receive treatment as standard care, not from a research protocol assignment.
What is the companion R21?
There isn't one. PAR-24-280 lists its companion funding opportunity as None. PAR-24-281 is an unrelated NLM G08 resource grant that has expired, so smaller pilot work needs a separate NIH notice.
Who should skip this route?
Skip it if the project prospectively assigns an intervention, tests treatment effects through a research protocol, or does not focus on musculoskeletal, rheumatic, or skin diseases.
Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
PAR-25-338 academic industrial R01 eligibility Guide
PAR 25 338 academic industrial guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-106 Cancer Nanotechnology R01 Eligibility Guide
NIH PAR-25-106 guide: NCI cancer nanotechnology R01 eligibility, clinical-trial-not-allowed fit, nanoscale criteria, and review checks.
PAR-25-317 family health R01 eligibility Guide
PAR 25 317 family health guide: 7 checks for eligibility, source status, budget, evidence, route fit, review criteria, and next steps in 2026.
PAR-25-112 language development R01 eligibility Guide
PAR 25 112 language development guide: 7 checks for eligibility, source status, budget, evidence, route fit, review criteria, and team readiness in 2026.
PAR-25-379 Native Health R01 Eligibility Guide
NIH PAR-25-379 guide: Native health intervention R01 eligibility, clinical-trial optional fit, community engagement, R01 versus R34, and review checks.
PAR-25-153 NCI Assay Screening R01 Eligibility Guide
NIH PAR-25-153 guide: NCI assay-development and screening R01 eligibility, clinical-trial-not-allowed fit, stages, and review checks.